![]() ![]() Other companies, including Biogen, are reportedly considering lawsuits also. Aimed at reducing US spending on medicines, it requires drug companies to pay rebates if the prices of medicines on the list rise faster than inflation.Īnother measure in the IRA – which gives Medicare the power to negotiate drug prices – has already sparked a legal challenge by Merck & Co. The list is one of the measures introduced in President Joe Biden’s controversial Inflation Reduction Act (IRA). The demands for the first round of rebates will arrive at drugmakers in 2025. The list of medicines in line for rebates is updated each quarter, according to the legislation, and any manufacturer that fails to pay the rebate will be fined 125% of the rebate amount. It’s possible, however, that the list may be revised again, as there is a comment period to allow discrepancies in the data to be highlighted and addressed.Īll the medicines come under Medicare Part B, which covers drugs administered to older patients in physicians’ offices or hospital outpatient departments. The latest list stands at 43 medicines, with some of the additions including Seagen’s Adcetris (brentuximab vedotin) for lymphomas, Amgen’s leukaemia therapy Blincyto (blinatumomab), and Amgen/AstraZeneca’s recently-approved severe asthma therapy Tezspire (tezepelumab).Īmgen has been hit particularly hard this time around, with four other therapies on the list, including its $3.6 billion osteoporosis therapy Prolia (denosumab) and Kyprolis (carfilzomib) for multiple myeloma. The original version of the list compiled by the US Centers for Medicare and Medicaid Services (CMS) covered 27 drugs, which was reduced to 20 a few weeks later with some prominent new therapies, including Gilead Sciences' CAR-T therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) for blood cancers, taken off. In a new update, the US government has more than doubled the size of the latest list of medicines subject to enforced rebates if their prices rise higher than inflation. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |